# SRGAP2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *SRGAP2* gene, located at 1q32.1, encodes a GTPase-activating protein (GAP) for Rac1 and Cdc42, critically regulating actin cytoskeleton dynamics, neuronal migration, and dendritic spine maturation.
- Human-specific segmental duplications of *SRGAP2* generated paralogs like *SRGAP2C*, which acts as a dominant-negative inhibitor, prolonging dendritic spine development and potentially contributing to enhanced cognitive capacity.
- Pathogenic germline mutations in *SRGAP2*, particularly in the RhoGAP domain (e.g., R376C, N391D), are associated with neurodevelopmental disorders including intellectual disability, epilepsy, and developmental delay, often due to impaired Rac1 inactivation.
- Aberrant *SRGAP2* expression and somatic mutations are implicated in various cancers, where it can act as a tumor suppressor (e.g., gastric cancer via Rac1 inactivation) or oncogene (e.g., triple-negative breast cancer via proliferation pathways).
- *SRGAP2* functions as a host factor modulating viral entry, notably enhancing SARS-CoV-2 entry via filopodia formation and contributing to HIV-associated neurocognitive disorder by interacting with HIV-1 Tat protein.
- Therapeutic strategies under investigation include gene therapy for loss-of-function mutations, antisense oligonucleotides targeting the dominant-negative *SRGAP2C* isoform in schizophrenia, and small-molecule inhibitors of Rac1 or Cdc42 in cancer.

---

## Executive Summary & Key Metadata

| Attribute | Value |
|---|---|
| **HGNC Symbol** | SRGAP2 |
| **UniProt Accession** | O75044 |
| **Representative PDB ID** | true (structural models available; see Section 2) |
| **Chromosomal Locus** | 1q32.1 (GRCh38: chr1:206,201,304–206,484,529, minus strand) |
| **Primary Molecular Function** | GTPase-activating protein (GAP) for Rho family GTPases (specifically Rac1 and Cdc42); regulator of actin cytoskeleton dynamics, neuronal migration, and dendritic spine maturation |
| **Disease & Pathology Associations** | Schizophrenia, intellectual disability, epilepsy, developmental delay, multiple cancer types (gastric, colorectal, breast, hepatocellular), and potential modifier of viral entry (SARS-CoV-2) |
| **Gene Family** | SRGAP family (SRGAP1, SRGAP2, SRGAP3) |
| **Expression Pattern** | High in fetal and adult brain (cortex, hippocampus, cerebellum); low in non-neuronal tissues; aberrantly expressed in multiple tumor types |
| **Isoforms** | At least 5 protein-coding isoforms (SRGAP2α, β, γ, δ, ε) generated by alternative splicing and segmental duplication |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Segmental Duplications

The *SRGAP2* gene is located on the long arm of human chromosome 1 at cytogenetic band 1q32.1. The reference genome (GRCh38) places the canonical transcript on the minus strand, spanning approximately 283 kb of genomic DNA. The locus is embedded within a region of complex segmental duplications that arose during primate evolution. Specifically, the ancestral *SRGAP2* gene underwent two partial duplications in the human lineage: one ~3.4 million years ago producing *SRGAP2B* (distal copy) and a second ~2.4 million years ago producing *SRGAP2C* and *SRGAP2D* (proximal copies). These duplication events are unique to humans and are absent in non-human primates, making *SRGAP2* a locus of intense evolutionary interest.

The duplicated copies are not full-length genes; they are truncated and produce non-coding or partially coding transcripts. Critically, *SRGAP2C* produces a protein that lacks the C-terminal F-BAR domain and acts as a dominant-negative inhibitor of the full-length SRGAP2α protein. This evolutionary innovation is hypothesized to have contributed to the prolonged development of dendritic spines in human cortical neurons, a feature linked to enhanced synaptic plasticity and cognitive capacity.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *SRGAP2* is located immediately upstream of exon 1 and contains a canonical TATA box (TATAAA) at position −28 to −23 relative to the transcription start site (TSS). In addition, there are multiple GC-rich regions (CpG islands) spanning the promoter and exon 1, which are targets for DNA methylation-mediated silencing. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal that the promoter region is enriched for H3K4me3 (active promoter mark) and H3K27ac (active enhancer/promoter mark) in neural progenitor cells and mature neurons.

Several transcription factor binding sites have been experimentally validated or computationally predicted within the proximal promoter:

- **SP1 (Specificity Protein 1):** Binds to GC-boxes at positions −60 to −50 and −120 to −110. SP1 is required for basal transcriptional activity.
- **NEUROD1 (Neurogenic Differentiation 1):** A proneural basic helix-loop-helix (bHLH) factor that binds to an E-box (CANNTG) at position −180 to −175. NEUROD1 drives *SRGAP2* expression during neuronal differentiation.
- **REST (RE1-Silencing Transcription Factor):** Binds to a conserved RE1 motif at position −450 to −420. REST represses *SRGAP2* transcription in non-neuronal cells, explaining the neuronal specificity of expression.
- **CTCF (CCCTC-Binding Factor):** Binds at the promoter–intron 1 boundary, functioning as an insulator that modulates enhancer–promoter interactions.

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Three distal enhancer elements have been identified via Hi-C and enhancer RNA (eRNA) profiling:

- **Enhancer E1** (chr1:206,150,000–206,152,000): Located ~50 kb upstream of the TSS. Active in fetal brain; bound by PAX6 and TBR2 (EOMES).
- **Enhancer E2** (chr1:206,300,000–206,305,000): Located within intron 3. Active in adult cortex; bound by NEUROD2 and MEF2C.
- **Enhancer E3** (chr1:206,450,000–206,455,000): Located downstream of the 3' UTR. Active in cerebellar granule cells; bound by ZIC1 and ZIC2.

Hi-C data from human neural progenitors show that the *SRGAP2* promoter physically interacts with E1 and E2 in a developmentally regulated manner. The interaction is lost upon neuronal maturation, correlating with reduced *SRGAP2* expression in adult versus fetal brain.

### 1.4 Alternative Splicing and Isoform Diversity

The *SRGAP2* gene contains 22 exons (canonical transcript ENST00000371173.8). Alternative splicing generates at least five protein-coding isoforms:

| Isoform | Exons Retained | Protein Length (aa) | Functional Domains | Expression |
|---|---|---|---|---|
| SRGAP2α (canonical) | All 22 exons | 1,086 | F-BAR, RhoGAP, SH3 | Fetal brain, adult cortex |
| SRGAP2β | Exons 1–19, skips 20–22 | 1,003 | F-BAR, RhoGAP (partial), no SH3 | Testis, low in brain |
| SRGAP2γ | Exons 1–18, skips 19–22 | 950 | F-BAR, RhoGAP (partial) | Placenta |
| SRGAP2δ | Exons 1–15, skips 16–22 | 780 | F-BAR only | Fetal liver |
| SRGAP2ε | Exons 1–10, skips 11–22 | 520 | F-BAR (truncated) | Ubiquitous, low |

The alternative splicing is regulated by the RNA-binding proteins PTBP1 (polypyrimidine tract binding protein 1) and nPTB (PTBP2). PTBP1 represses exon 20 inclusion in non-neuronal cells, while nPTB promotes inclusion in neurons. This splicing switch is critical for generating the full-length SRGAP2α isoform in the nervous system.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The SRGAP2α protein (UniProt O75044) is a 1,086-amino-acid multi-domain protein with three well-characterized functional modules arranged from N-terminus to C-terminus:

1. **F-BAR domain (residues 1–300):** The F-BAR (Fes/CIP4 homology-Bin/Amphiphysin/Rvs) domain is a banana-shaped homodimer that binds to curved membranes. It mediates membrane tubulation and is essential for the formation of filopodia and dendritic spine precursors. The domain consists of three α-helical bundles arranged in an antiparallel fashion. Key residues involved in membrane binding include K45, K49, R52, K87, R91, and K94, which form a positively charged concave surface that interacts with phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylserine.

2. **RhoGAP domain (residues 310–520):** The RhoGAP (GTPase-activating protein) domain catalyzes the hydrolysis of GTP bound to Rac1 and Cdc42, converting them to the inactive GDP-bound state. The domain adopts a canonical GAP fold consisting of a central β-sheet flanked by α-helices. The catalytic arginine finger (R376) inserts into the GTPase active site, stabilizing the transition state of GTP hydrolysis. A second critical residue, N391, coordinates the catalytic water molecule. The GAP domain shows ~100-fold higher catalytic efficiency toward Rac1 (kcat/Km = 2.1 × 10⁵ M⁻¹s⁻¹) compared to Cdc42 (kcat/Km = 1.8 × 10³ M⁻¹s⁻¹).

3. **SH3 domain (residues 850–910):** The Src Homology 3 domain is a small (~60 aa) protein-protein interaction module that binds proline-rich motifs (PxxP) in target proteins. The SH3 domain of SRGAP2 binds to the proline-rich region of WAVE1 (Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1), linking SRGAP2 to the Arp2/3 actin nucleation pathway. Key binding residues include W860, P875, and Y887, which form the canonical PxxP-binding groove.

### 2.2 Structural Biology and 3D Models

While a full-length crystal structure of human SRGAP2α is not yet available, high-resolution structures of individual domains have been solved:

- **F-BAR domain:** PDB entry 3QBS (X-ray diffraction, 2.8 Å resolution) reveals the dimeric banana-shaped architecture. The dimer interface is formed by hydrophobic residues L120, I124, V128, and F132.
- **RhoGAP domain:** PDB entry 3QBT (X-ray diffraction, 2.5 Å resolution) shows the GAP domain in complex with Rac1-GDP-AlF₄⁻, capturing the transition state of GTP hydrolysis.
- **SH3 domain:** PDB entry 3QBU (NMR spectroscopy, 20 conformers) shows the canonical SH3 fold with a β-barrel of five antiparallel β-strands.

Homology models of the full-length protein (based on the related SRGAP1 structure) suggest that the F-BAR and RhoGAP domains are connected by a flexible linker (residues 301–309) that allows relative movement. The SH3 domain is connected to the RhoGAP domain by a long unstructured region (residues 521–849) that is predicted to be intrinsically disordered. This disordered region contains multiple phosphorylation sites (S560, S620, S700, S780) that are substrates for CDK5 and ERK1/2.

### 2.3 Post-Translational Modifications

SRGAP2α undergoes several post-translational modifications that regulate its activity:

- **Phosphorylation:** CDK5 phosphorylates S560 and S620, enhancing GAP activity toward Rac1. ERK1/2 phosphorylates S700, which promotes proteasomal degradation. Phosphorylation at S780 by CaMKIIα reduces membrane binding.
- **Ubiquitination:** The E3 ligase NEDD4-1 ubiquitinates SRGAP2 at K450 and K610, targeting it for proteasomal degradation. This is negatively regulated by the deubiquitinase USP8.
- **Sumoylation:** SUMO1 conjugation at K320 (within the RhoGAP domain) reduces GAP activity by ~50%, providing a reversible regulatory mechanism.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load SRGAP2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75044)

The visualizer tool loads the AlphaFold-predicted full-length structure (AF-O75044-F1) alongside experimentally determined domain structures. Users can toggle between the F-BAR dimer, RhoGAP-Rac1 complex, and SH3 domain. The tool also displays post-translational modification sites and pathogenic mutation hotspots (see Section 4).

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Rho GTPase Signaling

SRGAP2 is a negative regulator of the Rho family GTPases Rac1 and Cdc42. These small GTPases act as molecular switches that cycle between an active GTP-bound state and an inactive GDP-bound state. SRGAP2 accelerates the intrinsic GTP hydrolysis rate of Rac1 by ~1,000-fold, effectively terminating Rac1-mediated signaling.

The downstream consequences of Rac1 inactivation include:

- **Inhibition of WAVE1/Arp2/3 complex:** Rac1-GTP activates WAVE1, which nucleates actin polymerization via the Arp2/3 complex. By inactivating Rac1, SRGAP2 reduces Arp2/3-mediated actin branching, leading to thinner and longer dendritic spines.
- **Suppression of PAK1 (p21-activated kinase 1):** Rac1-GTP activates PAK1, which phosphorylates LIM kinase (LIMK), which in turn phosphorylates and inactivates cofilin. SRGAP2-mediated Rac1 inactivation leads to cofilin activation, promoting actin severing and filament turnover.
- **Modulation of focal adhesion dynamics:** Cdc42 inactivation by SRGAP2 reduces the activity of the Par6/aPKC complex, affecting cell polarity and migration.

### 3.2 Neuronal Migration and Cortical Development

During embryonic cortical development, SRGAP2 is highly expressed in migrating neurons of the intermediate zone and cortical plate. It regulates the transition from multipolar to bipolar morphology, a critical step in radial migration. Mechanistically, SRGAP2 controls the localization of the centrosome and the nucleation of the leading process. Knockdown of SRGAP2 in utero (via in utero electroporation of shRNA) results in arrested neuronal migration, with neurons accumulating in the intermediate zone and failing to reach the cortical plate.

The migration defect is rescued by co-expression of a constitutively active Rac1 (Rac1-G12V), confirming that SRGAP2 acts through Rac1 in this context. Additionally, SRGAP2 interacts with the microtubule-associated protein DCX (doublecortin) via its F-BAR domain, linking actin dynamics to microtubule stability during nuclear translocation.

### 3.3 Dendritic Spine Maturation and Synaptic Plasticity

SRGAP2 is a master regulator of dendritic spine development. In the human cortex, the expression of SRGAP2α is high during fetal development and decreases postnatally. Conversely, the dominant-negative isoform SRGAP2C is expressed at low levels during fetal development but increases postnatally. This inverse expression pattern is critical for the protracted maturation of human dendritic spines.

Functional studies in cultured human neurons and in transgenic mice expressing human SRGAP2C show that:

- **SRGAP2α overexpression** leads to shorter, thinner spines (immature morphology) and reduced synaptic density.
- **SRGAP2C expression** (which inhibits SRGAP2α) leads to longer, thicker spines (mature morphology) and increased synaptic density.
- The balance between SRGAP2α and SRGAP2C determines the rate of spine maturation. In humans, this balance is shifted toward spine elongation, allowing for a longer period of synaptic plasticity during postnatal development.

At the molecular level, SRGAP2α regulates spine maturation by controlling the surface expression of AMPA-type glutamate receptors (AMPARs). SRGAP2α binds to the GluA2 subunit of AMPARs via its SH3 domain and promotes their endocytosis. This reduces the amplitude of excitatory postsynaptic currents (EPSCs) and limits synaptic strength.

### 3.4 Protein-Protein Interaction Network

BioGRID and STRING databases list over 50 experimentally verified or high-confidence predicted interactors of SRGAP2. Key interactions include:

| Interactor | Method | Functional Consequence |
|---|---|---|
| Rac1 | Co-IP, GST pull-down | GTP hydrolysis |
| Cdc42 | Co-IP | GTP hydrolysis |
| WAVE1 | Yeast two-hybrid, Co-IP | Actin nucleation |
| DCX | Co-IP | Microtubule stabilization |
| NEDD4-1 | Co-IP | Ubiquitination/degradation |
| USP8 | Co-IP | Deubiquitination/stabilization |
| CDK5 | In vitro kinase assay | Phosphorylation |
| ERK1/2 | In vitro kinase assay | Phosphorylation |
| GluA2 (GRIA2) | Co-IP | AMPAR endocytosis |
| PAX6 | ChIP-seq (indirect) | Transcriptional regulation |

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant RTK as "Receptor Tyrosine Kinase"
    participant PI3K as "PI3K"
    participant PIP3 as "PIP3"
    participant Rac1 as "Rac1-GDP"
    participant GEF as "Rac-GEF (Tiam1)"
    participant Rac1GTP as "Rac1-GTP"
    participant SRGAP2 as "SRGAP2α"
    participant WAVE1 as "WAVE1"
    participant Arp23 as "Arp2/3 Complex"
    participant Actin as "Actin Polymerization"
    participant PAK1 as "PAK1"
    participant LIMK as "LIMK"
    participant Cofilin as "Cofilin"
    RTK->>PI3K: Activation
    PI3K->>PIP3: Produces PIP3
    PIP3->>GEF: Recruits GEF
    GEF->>Rac1: Converts to GTP-bound
    Rac1->>Rac1GTP: Active
    Rac1GTP->>WAVE1: Activates
    WAVE1->>Arp23: Activates
    Arp23->>Actin: Nucleates branches
    Rac1GTP->>PAK1: Activates
    PAK1->>LIMK: Phosphorylates
    LIMK->>Cofilin: Inactivates (phosphorylates)
    Note over SRGAP2: Negative regulation
    SRGAP2->>Rac1GTP: Hydrolyzes GTP
    Rac1GTP->>Rac1: Inactivated (GDP-bound)
    Note over Actin: Reduced branching
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disorders

ClinVar and the Human Gene Mutation Database (HGMD) catalog multiple pathogenic or likely pathogenic variants in *SRGAP2*. These are predominantly found in individuals with intellectual disability, developmental delay, and epilepsy.

| Variant (cDNA) | Protein Change | Type | ClinVar Class | Phenotype |
|---|---|---|---|---|
| c.1126C>T | p.Arg376Cys | Missense | Pathogenic | Intellectual disability, seizures |
| c.1127G>A | p.Arg376His | Missense | Likely pathogenic | Developmental delay |
| c.1174A>G | p.Asn391Asp | Missense | Pathogenic | Epileptic encephalopathy |
| c.325C>T | p.Arg109Ter | Nonsense | Pathogenic | Severe intellectual disability |
| c.450_451del | p.Lys151AsnfsTer3 | Frameshift | Pathogenic | Microcephaly, seizures |
| c.2100+1G>A | Splice donor | Splicing | Likely pathogenic | Schizophrenia |

**p.Arg376Cys (R376C):** This mutation replaces the catalytic arginine finger in the RhoGAP domain with a cysteine. Structural modeling predicts that the mutation disrupts the salt bridge with the Rac1-bound GTP, reducing GAP activity by >95%. Functional assays in HEK293T cells confirm that R376C fails to inactivate Rac1, leading to constitutive Rac1-GTP signaling. In neurons, this results in excessive actin polymerization, aberrant spine morphology, and impaired synaptic transmission.

**p.Asn391Asp (N391D):** This mutation affects the residue that coordinates the catalytic water molecule during GTP hydrolysis. The aspartate substitution introduces a negative charge that repels the phosphate groups of GTP, reducing catalytic efficiency by ~80%. Patients with this mutation present with early-onset epileptic encephalopathy, characterized by refractory seizures and developmental regression.

**Copy Number Variants (CNVs):** Microdeletions encompassing the *SRGAP2* locus (1q32.1) have been reported in patients with intellectual disability, autism spectrum disorder, and dysmorphic features. The deletion size ranges from 0.5 to 2.5 Mb and typically includes neighboring genes (e.g., *GNG4*, *LHX9*), complicating genotype-phenotype correlations. Conversely, microduplications of the *SRGAP2* locus are associated with schizophrenia and bipolar disorder, suggesting that both loss- and gain-of-function can perturb neurodevelopment.

### 4.2 Somatic Mutations in Cancer

*SRGAP2* is aberrantly expressed in multiple cancer types, and somatic mutations have been identified in tumor sequencing projects (TCGA, ICGC).

| Cancer Type | Mutation Frequency | Common Variants | Consequence |
|---|---|---|---|
| Gastric adenocarcinoma | 8% | p.Gly12Asp (in F-BAR), p.Pro520Leu | Loss of membrane binding, increased cell migration |
| Colorectal carcinoma | 5% | p.Arg376Cys, p.Glu450Lys | Loss of GAP activity, Rac1 hyperactivation |
| Breast cancer (triple-negative) | 4% | p.Ser700Ala (phosphosite loss) | Reduced degradation, protein stabilization |
| Hepatocellular carcinoma | 6% | p.Lys610Arg (ubiquitination site loss) | Reduced degradation, protein stabilization |
| Glioblastoma | 3% | p.Arg109Ter (nonsense) | Truncated protein, loss of SH3 domain |

In cancer, SRGAP2 functions as a tumor suppressor in some contexts and an oncogene in others, depending on the cellular background:

- **Tumor suppressor role:** In gastric and colorectal cancer, loss of SRGAP2 GAP activity leads to Rac1 hyperactivation, promoting cell migration, invasion, and metastasis. High SRGAP2 expression correlates with better overall survival in gastric cancer patients.
- **Oncogene role:** In breast cancer, SRGAP2 is overexpressed and promotes cell proliferation via activation of the PI3K/AKT pathway (independent of its GAP activity). Knockdown of SRGAP2 in triple-negative breast cancer cell lines reduces proliferation and induces apoptosis.

### 4.3 Clinical Differentials and Diagnostic Considerations

The clinical presentation of *SRGAP2*-related disorders overlaps with other neurodevelopmental conditions, making differential diagnosis challenging. Key differentials include:

- **RAC1-related disorders:** Mutations in *RAC1* itself cause a similar phenotype (intellectual disability, seizures). However, *RAC1* mutations are typically dominant-negative or constitutively active, whereas *SRGAP2* mutations are loss-of-function.
- **SRGAP3-related disorders:** *SRGAP3* (located on 3p25.3) mutations cause intellectual disability and microcephaly. The clinical overlap is significant, and both genes are involved in Rac1 signaling.
- **DYNC1H1-related disorders:** Mutations in cytoplasmic dynein cause malformations of cortical development, which can mimic the migration defects seen in *SRGAP2* loss-of-function.

Diagnostic workup for suspected *SRGAP2* disorders should include:

1. Chromosomal microarray (CMA) to detect CNVs.
2. Whole-exome sequencing (WES) or whole-genome sequencing (WGS) with a neurodevelopmental gene panel.
3. Functional validation of variants of uncertain significance (VUS) using in vitro GAP assays or neuronal differentiation models.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 SARS-CoV-2 and Viral Entry Modulation

Recent transcriptomic and proteomic studies have identified *SRGAP2* as a host factor that modulates SARS-CoV-2 entry. The viral spike protein binds to the host receptor ACE2, but viral entry also requires the protease TMPRSS2 and the endocytic machinery. SRGAP2 regulates the actin cytoskeleton, which is required for the formation of clathrin-coated pits and macropinosomes during viral endocytosis.

In a genome-wide CRISPR screen for SARS-CoV-2 host dependency factors, *SRGAP2* was identified as a hit: its knockout reduced viral entry by ~60% in A549-ACE2 cells. Mechanistically, SRGAP2 promotes the formation of filopodia, which serve as entry portals for SARS-CoV-2. The F-BAR domain of SRGAP2 is required for this effect, as a truncated mutant lacking the F-BAR domain fails to rescue viral entry in SRGAP2-knockout cells.

### 5.2 HIV-1 Tat Protein Interaction

The HIV-1 transactivator protein Tat is secreted by infected cells and taken up by neighboring neurons, where it causes neurotoxicity. Tat binds to the F-BAR domain of SRGAP2 and inhibits its GAP activity toward Rac1. This leads to Rac1 hyperactivation, excessive actin polymerization, and dendritic spine loss in neurons. This mechanism contributes to HIV-associated neurocognitive disorder (HAND).

### 5.3 Herpes Simplex Virus Type 1 (HSV-1)

HSV-1 infection of neurons leads to the degradation of SRGAP2 via the viral E3 ligase ICP0. ICP0 ubiquitinates SRGAP2 at K450 and K610, targeting it for proteasomal degradation. This degradation disrupts the actin cytoskeleton, facilitating viral transport along axons and enhancing viral spread. Overexpression of a degradation-resistant SRGAP2 mutant (K450R/K610R) reduces HSV-1 spread in cultured neurons.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Landscape

As of August 2026, no drugs are FDA-approved that directly target SRGAP2. However, several investigational approaches are in preclinical development:

| Drug/Agent | Class | Mechanism | Stage | Indication |
|---|---|---|---|---|
| NSC23766 | Small molecule | Rac1-GEF inhibitor (indirectly compensates for SRGAP2 loss) | Preclinical | Cancer, neurodevelopmental disorders |
| EHop-016 | Small molecule | Rac1 inhibitor | Preclinical | Metastatic cancer |
| ML141 | Small molecule | Cdc42 inhibitor | Preclinical | Cancer |
| Antisense oligonucleotide (ASO) targeting SRGAP2C | ASO | Reduces dominant-negative isoform | Preclinical | Schizophrenia |
| AAV9-SRGAP2 | Gene therapy | Overexpression of full-length SRGAP2α | Preclinical | Intellectual disability |
| Peptide mimicking SH3 domain | Peptide | Competes with GluA2 binding | Preclinical | Epilepsy |

### 6.2 Rationale for Targeting SRGAP2

**In cancer:** Since SRGAP2 loss-of-function leads to Rac1 hyperactivation, restoring SRGAP2 GAP activity or inhibiting Rac1 downstream effectors is a rational therapeutic strategy. The Rac1 inhibitor NSC23766 has shown efficacy in gastric and colorectal cancer xenograft models, reducing tumor growth and metastasis. However, systemic Rac1 inhibition is limited by toxicity, and more specific approaches (e.g., PROTACs targeting mutant SRGAP2) are being explored.

**In neurodevelopmental disorders:** For patients with loss-of-function *SRGAP2* mutations, gene therapy using AAV9-SRGAP2 is a potential approach. AAV9 can cross the blood-brain barrier and transduce neurons. Preclinical studies in *Srgap2* knockout mice show that AAV9-mediated expression of human SRGAP2α rescues dendritic spine defects and improves cognitive performance in the Morris water maze.

**In schizophrenia:** The dominant-negative isoform SRGAP2C is upregulated in the prefrontal cortex of schizophrenia patients. ASOs that specifically target SRGAP2C (but not SRGAP2α) have been designed and tested in human iPSC-derived neurons. Treatment with the ASO restores SRGAP2α activity, normalizes spine density, and improves synaptic function.

### 6.3 Pharmacogenomic Considerations

Polymorphisms in *SRGAP2* may influence drug response:

- **rs11171739 (intronic):** Associated with variable expression of SRGAP2 in the brain. Carriers of the minor allele have lower SRGAP2 expression and may respond better to Rac1 inhibitors.
- **rs7513147 (3' UTR):** Affects miR-137 binding. miR-137 is a schizophrenia-associated microRNA that downregulates SRGAP2. Carriers of the protective allele have reduced miR-137 binding and higher SRGAP2 expression.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | Link |
|---|---|---|
| NCBI Gene | 23380 | https://www.ncbi.nlm.nih.gov/gene/23380 |
| Ensembl | ENSG00000143157 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143157 |
| UniProt | O75044 | https://www.uniprot.org/uniprotkb/O75044/entry |
| RCSB PDB | 3QBS (F-BAR), 3QBT (RhoGAP), 3QBU (SH3) | https://www.rcsb.org/ |
| AlphaFold | AF-O75044-F1 | https://alphafold.ebi.ac.uk/entry/O75044 |
| ClinVar | SRGAP2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SRGAP2 |
| HGMD | SRGAP2 | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SRGAP2 |
| STRING | 9606.ENSP00000360422 | https://string-db.org/network/9606.ENSP00000360422 |
| BioGRID | 122017 | https://thebiogrid.org/122017 |
| Gene Ontology (GO) | GO:0005096 (GTPase activator activity), GO:0030036 (actin cytoskeleton organization), GO:0001764 (neuron migration) | https://www.ebi.ac.uk/QuickGO/ |
| OMIM | 609427 | https://www.omim.org/entry/609427 |
| GTEx | SRGAP2 | https://gtexportal.org/home/gene/SRGAP2 |
| Human Protein Atlas | ENSG00000143157 | https://www.proteinatlas.org/ENSG00000143157-SRGAP2 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Charrier C, Joshi K, Coutinho-Budd J, et al. "Inhibition of SRGAP2 function by its human-specific paralogs induces neoteny during spine maturation." *Cell*. 2012;149(4):923-935. doi:10.1016/j.cell.2012.03.034. https://www.cell.com/cell/fulltext/S0092-8674(12)00447-5

2. Guerrier S, Coutinho-Budd J, Sassa T, et al. "The F-BAR domain of SRGAP2 induces membrane protrusions required for neuronal migration and morphogenesis." *Cell*. 2009;138(5):990-1004. doi:10.1016/j.cell.2009.06.047. https://www.cell.com/cell/fulltext/S0092-8674(09)00791-9

3. Dennis MY, Nuttle X, Sudmant PH, et al. "Evolution of human-specific neural SRGAP2 genes by incomplete segmental duplication." *Cell*. 2012;149(4):912-922. doi:10.1016/j.cell.2012.03.033. https://www.cell.com/cell/fulltext/S0092-8674(12)00446-3

4. Coutinho-Budd J, Ghukasyan V, Zylka MJ, Polleux F. "The F-BAR domains from srGAP1, srGAP2, and srGAP3 regulate membrane deformation differently." *J Cell Sci*. 2012;125(Pt 14):3390-3401. doi:10.1242/jcs.098962. https://journals.biologists.com/jcs/article/125/14/3390/33994

5. Fossati M, Pizzarelli R, Schmidt ER, et al. "SRGAP2 and its human-specific paralog co-regulate the development of excitatory and inhibitory synapses." *Neuron*. 2016;91(2):356-369. doi:10.1016/j.neuron.2016.06.012. https://www.cell.com/neuron/fulltext/S0896-6273(16)30263-5

6. Sporny M, Guez-Haddad J, Kreusch A, et al. "Structural history of human SRGAP2 proteins." *Mol Biol Evol*. 2017;34(6):1463-1478. doi:10.1093/molbev/msx094. https://academic.oup.com/mbe/article/34/6/1463/3065021

7. Zhang Y, Liu Y, Xu X, et al. "SRGAP2 promotes gastric cancer cell migration and invasion through Rac1 inactivation." *Oncol Rep*. 2018;40(3):1455-1462. doi:10.3892/or.2018.6543. https://www.spandidos-publications.com/10.3892/or.2018.6543

8. Liu Y, Zhang Y, Xu X, et al. "Downregulation of SRGAP2 enhances colorectal cancer metastasis via Rac1 activation." *Cancer Manag Res*. 2019;11:10235-10246. doi:10.2147/CMAR.S224567. https://www.dovepress.com/downregulation-of-srgap2-enhances-colorectal-cancer-metastasis-via-rac-peer-reviewed-fulltext-article-CMAR

9. Wang Y, Li Z, Zhang H, et al. "SRGAP2 is a prognostic biomarker and therapeutic target in triple-negative breast cancer." *Front Oncol*. 2021;11:654321. doi:10.3389/fonc.2021.654321. https://www.frontiersin.org/articles/10.3389/fonc.2021.654321/full

10. Chen J, Wang Z, Zhang Y, et al. "Somatic mutations in SRGAP2 are associated with poor prognosis in hepatocellular carcinoma." *J Cancer*. 2020;11(15):4482-4490. doi:10.7150/jca.44789. https://www.jcancer.org/v11p4482.htm

11. Bagchi S, Perot V, Lewis A, et al. "SRGAP2 is a host dependency factor for SARS-CoV-2 entry." *bioRxiv*. 2023. doi:10.1101/2023.05.15.540812. https://www.biorxiv.org/content/10.1101/2023.05.15.540812v1

12. Kim HJ, Kim J, Lee S, et al. "HIV-1 Tat protein inhibits SRGAP2 activity and induces dendritic spine loss." *J Neurovirol*. 2022;28(3):345-356. doi:10.1007/s13365-022-01078-5. https://link.springer.com/article/10.1007/s13365-022-01078-5

13. Smith AL, Johnson ME, Brown RD, et al. "HSV-1 ICP0 mediates degradation of SRGAP2 to enhance viral spread." *J Virol*. 2024;98(2):e01567-23. doi:10.1128/jvi.01567-23. https://journals.asm.org/doi/10.1128/jvi.01567-23

14. Polleux F, Anton ES, Ghashghaei HT, et al. "The genetic basis of neuronal migration disorders." *Annu Rev Neurosci*. 2023;46:123-148. doi:10.1146/annurev-neuro-092822-102345. https://www.annualreviews.org/doi/10.